-
1
-
-
84866761034
-
-
November, Available at Accessed November 28, 2009
-
World Health Organization. Diabetes: fact sheet (no.312). November 2009. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed November 28, 2009.
-
(2009)
Diabetes: Fact Sheet (no.312)
-
-
-
2
-
-
61349099439
-
Diagnosis and classification of diabetes mellitus
-
American Diabetes Association
-
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62-S67.
-
(2009)
Diabetes Care
, vol.32
, Issue.SUPPL. 1
-
-
-
3
-
-
60449089649
-
American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
4
-
-
84925564345
-
-
Onglyza -package insert-. Princeton, NJ: Bristol-Myers Squibb Company, 2009
-
Onglyza -package insert-. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
-
-
-
-
5
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
6
-
-
33845344395
-
Plasma insulin response to oral and intravenous glucose administration
-
Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1966;24:1076-1082.
-
(1966)
J Clin Endocrinol Metab
, vol.24
, pp. 1076-1082
-
-
Elrick, H.1
Stimmler, L.2
Hlad Jr., C.J.3
-
7
-
-
0142258657
-
Gut peptides and type 2 diabetes mellitus treatment
-
Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3:365-372.
-
(2003)
Curr Diab Rep
, vol.3
, pp. 365-372
-
-
Ahren, B.1
-
8
-
-
0022461548
-
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
-
Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocr Rev. 1986;63:492-498.
-
(1986)
J Clin Endocr Rev
, vol.63
, pp. 492-498
-
-
Ma, N.1
Homberger, E.2
Siegel, E.G.3
-
9
-
-
0037312818
-
Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
-
Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
-
(2003)
Mol Endocrinol
, vol.17
, pp. 161-171
-
-
Drucker, D.J.1
-
10
-
-
0034838323
-
Glucose-dependent insulinotropic polypeptide is a growth factor for beta cells by pleiotropic signaling
-
Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta cells by pleiotropic signaling. Mol Endocrinol. 2001;15:1559-1570.
-
(2001)
Mol Endocrinol
, vol.15
, pp. 1559-1570
-
-
Trumper, A.1
Trumper, K.2
Trusheim, H.3
-
11
-
-
0033520869
-
GIP biology and fat metabolism
-
Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66:91-103.
-
(2000)
Life Sci
, vol.66
, pp. 91-103
-
-
Yip, R.G.1
Wolfe, M.M.2
-
12
-
-
0028953577
-
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolites in vivo
-
Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolites in vivo. J Clin Endocrinol Metab. 1995;80:952-957.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 952-957
-
-
Deacon, C.F.1
Johnsen, A.H.2
Holst, J.J.3
-
13
-
-
0033619675
-
Dipeptidyl-peptidase IV (CD 26)-role in the inactivation of regulatory peptides
-
Mentlein R. Dipeptidyl-peptidase IV (CD 26) -role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
-
(1999)
Regul Pept
, vol.85
, pp. 9-24
-
-
Mentlein, R.1
-
14
-
-
73449117555
-
Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
-
Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-262.
-
(2009)
Adv Ther
, vol.26
, pp. 249-262
-
-
Tahrani, A.A.1
Piya, M.K.2
Barnett, A.H.3
-
15
-
-
70349333861
-
CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
-
Rosenstock J, Aguilar-Salinas C, Klein E, et al. CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401-2411.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2401-2411
-
-
Rosenstock, J.1
Aguilar-Salinas, C.2
Klein, E.3
-
16
-
-
68949212458
-
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomized controlled trial
-
Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract. 2009;63:1395-1406.
-
(2009)
Int J Clin Pract
, vol.63
, pp. 1395-1406
-
-
Chacra, A.R.1
Tan, G.H.2
Apanovitch, A.3
-
17
-
-
69549135336
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone
-
Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32: 1649-1655.
-
(2009)
Diabetes Care
, vol.32
, pp. 1649-1655
-
-
Defronzo, R.A.1
Hissa, M.N.2
Garber, A.J.3
-
18
-
-
65549123794
-
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
-
Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 611-622
-
-
Jadzinsky, M.1
Pfutzner, A.2
Paz-Pacheco, E.3
-
19
-
-
73149084956
-
For the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone
-
Hollander P, Li J, Allen E, et al; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-4819.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 4810-4819
-
-
Hollander, P.1
Li, J.2
Allen, E.3
|